An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies

Conclusion.CSYS proves to be clinically applicable and useful in disclosing genomic alterations relevant to cancer target therapies and revealing biomarkers for immune checkpoint inhibitors.Implications for Practice.The study describes a specially designed sequencing panel assay to detect genomic alterations and features of 450 cancer genes, including its overall workflow and rigorous clinical and analytical validations. The distribution of pan‐cancer tumor mutational burden, microsatellite instability, gene rearrangement, and long insertion and deletion mutations was assessed for the first time by this assay in a broad array of Chinese patients with cancer. The Cancer Sequencing YS panel and its validation study could serve as a blueprint for developing next‐generation sequencing‐based assays, particularly for the purpose of clinical application.

Source: The Oncologist - December 9, 2019 Category: Cancer & Oncology Authors: Jingyu Cao, Lijuan Chen, Heng Li, Hui Chen, Jicheng Yao, Shuo Mu, Wenjin Liu, Peng Zhang, Yuwei Cheng, Binbin Liu, Zhongxiang Hu, Donglin Chen, Hui Kang, Jinwei Hu, Aodi Wang, Weifeng Wang, Ming Yao, Gungwei Chrin, Xiaoting Wang, Wei Zhao, Lei Li, Luping Tags: Cancer Diagnostics and Molecular Pathology Source Type: research